📢 Cycuria’s Scientific Vision Featured in Drug Target Review article
We’re proud to share that 𝗣𝗿𝗼𝗳. 𝗗𝗿. Philipp Jost , Scientific Founder of Cycuria Therapeutics , is featured in Drug Target Review discussing innovative strategies to address relapse in acute myeloid leukemia ( AML ). In the article “𝙏𝙖𝙧𝙜𝙚𝙩𝙞𝙣𝙜 𝙞𝙣𝙛𝙡𝙖𝙢𝙢𝙖𝙩𝙤𝙧𝙮 𝙘𝙚𝙡𝙡 𝙙𝙚𝙖𝙩𝙝 𝙩𝙤 𝙩𝙖𝙘𝙠𝙡𝙚 𝙧𝙚𝙡𝙖𝙥𝙨𝙚 𝙞𝙣 𝘼𝙈𝙇”, Prof. Jost highlights how our synthetic cytokine-based approach […]
Cycuria Therapeutics Featured on the Base-to-Base Biotech Podcast!
Our CEO & Co-Founder, Nisit Khandelwal, joined host Jim Cornall on the 𝗕𝗮𝘀𝗲-𝘁𝗼-𝗕𝗮𝘀𝗲 𝗕𝗶𝗼𝘁𝗲𝗰𝗵 𝗣𝗼𝗱𝗰𝗮𝘀𝘁 to discuss Cycuria Therapeutics’ approach to treating some of the most hard-to-treat blood cancers! 🎧 Listen to the full podacst here: Base to Base biotech podcast 42 Jump to 32:44 timestamp for the interview.
Cycuria Publishes Groundbreaking Research in Science Translational Medicine Demonstrating Lymphotoxin Alpha Eradicates Acute Myeloid Leukemia
The study, led by Cycuria’s scientific founder, Prof. Dr. Philipp Jost , a clinician-scientist, and his research team, describes a natural tumor-suppressing mechanism mediated by lymphotoxin alpha (LTA). Read the full press release here: Cycuria Press Release on STM Publication_26112025
Interview with our CEO featured by ABA – INVEST in AUSTRIA!
We’re pleased to share an exclusive interview with our CEO featured by ABA – INVEST in AUSTRIA ! In this article, we talk about Cycuria Therapeutics ‚ journey as a startup from Graz and how we’re developing a cutting-edge targeted cancer therapy for patients in need. From our vision for precision oncology to why Austria […]
Cycuria Therapeutics Announces the Formation of a Distinguished Advisory Board and Significant Public Grant Funding from FFG and AWS
We’re proud to unveil exciting news from Cycuria Therapeutics. We’ve secured grant funding from two leading Austrian national bodies, FFG and AWS, and today announce our newly appointed Advisory Board, which unites distinguished leaders in corporate strategy, clinical haemato-oncology, protein engineering, early-stage drug discovery and development. Our distinguished advisory board consists of John Haurum, Bertolt Kreft, […]
Cycuria Wins the SPIRIT Startup Award 2025 in the Health Category
We are thrilled to announce that Cycuria has been honored with the SPIRIT Startup Award in the Health category ! This prestigious recognition highlights our commitment to pioneering innovation in the biotech space and reinforces our vision of transforming scientific breakthroughs into impactful therapies. The award ceremony was an inspiring evening, celebrating cutting-edge startups pushing […]
Cycuria Founder, Prof. Dr. Philipp Jost, Highlights the Strategic Advantages and Opportunities at Medical Science City Graz
We’re thrilled to share recent press coverage highlighting Cycuria Therapeutics‘ innovative approach in oncology and our choice to establish roots in Graz’s Medical Science City, a growing hub for biotech and healthcare innovation. Read the full conversation of our scientific founder, Prof. Dr. Philipp Jost, with the press outlet MEDitio here .
Cycuria Featured in the Austrian National Newspaper Die Presse
Die Presse, one of Austria’s most respected national newspapers, features our scientific breakthrough in cancer research led by our scientific founder, Prof. Dr. Philipp Jost. Read the full article here.